Trials / Completed
CompletedNCT06723405
Efficacy Study of EVO301 in Moderate to Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Study of EVO301 in Adults With Atopic Dermatitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 71 (actual)
- Sponsor
- Evommune, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 2a efficacy and safety study of EVO301 for the treatment of adults with atopic dermatitis.
Detailed description
This is a Phase 2a efficacy and safety study of intravenous EVO301 in adults with moderate to severe atopic dermatitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | EVO301 | Intravenous EVO301 |
| BIOLOGICAL | Placebo | Placebo |
Timeline
- Start date
- 2025-02-13
- Primary completion
- 2025-11-17
- Completion
- 2025-11-17
- First posted
- 2024-12-09
- Last updated
- 2025-12-04
Locations
12 sites across 2 countries: Australia, New Zealand
Source: ClinicalTrials.gov record NCT06723405. Inclusion in this directory is not an endorsement.